An expansion of Genentech’s (Roche’s U.S. subsidiary) 75-acre campus to add a new device fill-finish manufacturing facility. The investment will double the size of the existing facility and is expected to create 250 high-wage manufacturing jobs and support an additional 200 construction jobs.

Part of a larger, previously announced $50 billion company investment.

A new, state-of-the-art multi-modal manufacturing campus, designed to accelerate the delivery of next-generation medicines to patients. Project is estimated to create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.

Part of a larger, previously announced $40 billion company investment.

Expansion of a strategic partnership between Resilience and Eli Lilly to increase U.S. manufacturing of innovative medicines treating diabetes and obesity. The partnership is expected to create at least 400 new high-skilled jobs in the Cincinnati region.

Part of a larger, previously announced $23 billion company investment.

Expansion of IV solutions manufacturing capacity through a new 500,000 square foot facility at the company's Austin, Texas campus. The project is part of a joint venture between Otsuka and ICU Medical Inc. to improve IV solutions supply chain resiliency and accelerate new product innovation. 

Construction of a new state-of-the-art distribution facility to scale the company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients.

Part of a larger, previously announced $55 billion company investment.

Expansion of two existing facilities across Ohio.

In Bedford, the company is investing $51 million to expand its injectable pharmaceutical manufacturing capabilities, IV bag production, and warehousing and distribution operations. The project is expected to create 300 new jobs.

In Columbus, $216 million is being invested to expand oral solid dose and nasal inhalation manufacturing operations, creating 50 new jobs.

These investments are part of a larger, $1 billion company investment announced in June 2025.

Investment across two of the company’s three sites in Lebanon, Indiana.

The investment will incorporate new process designs and technologies at one of the company's future active pharmaceutical ingredient sites as well as at its first dedicated genetic medicine manufacturing facility.

Part of a larger, previously announced $23 billion company investment.

Additional investment at the company’s Juncos biologics manufacturing facility. 

Combined with a $650 million investment in September 2025, this additional investment brings the company’s total commitment to this facility to $950 million.

Finalized plans to build a manufacturing facility focused on active pharmaceutical ingredients(API) for solid dosage tablets, capsules and RNA therapeutics. The 56,200-square-foot site will expand the company’s presence in North Carolina to five facilities.

Plans were initially announced in November 2025.

Part of a larger, previously announced $23 billion company investment.

A 185-acre campus that will integrate advanced manufacturing and laboratory technologies with AI to support the production of the company’s immunology, neuroscience and oncology medicines.

The project will create about 734 jobs in engineering, manufacturing operations and other technical roles and will generate more than 2,000 construction jobs during campus development.

Part of a larger, previously announced $100 billion company investment.